Minimal Residual Disease (MRD) Negativity and Lenalidomide Maintainence Therapy are Associated with Superior Survival Outcomes in Multiple Myeloma

被引：0

作者：

Gopalakrishnan, Ragisha ^{[1
]}

Engelhardt, Brian G. ^{[1
]}

Sengsayedeth, Salyka ^{[1
]}

Culos, Kathryn A. ^{[2
]}

Byrne, Michael T. ^{[3
]}

Goodman, Stacey ^{[1
]}

Savani, Bipin N. ^{[3
]}

Chinratanalab, Wichai ^{[1
]}

Jagasia, Madan ^{[4
]}

Cornell, Robert Frank ^{[1
]}

Kassim, Adetola A. ^{[3
]}

机构：

[1] Vanderbilt Univ, Med Ctr, Nashville, TN USA

[2] Vanderbilt Univ, Med Ctr, Pharm, Nashville, TN USA

[3] Vanderbilt Univ, Med Ctr, Hematol Oncol, Nashville, TN USA

[4] Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Nashville, TN USA

来源：

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2018年 / 24卷 / 03期

关键词：

D O I：

10.1016/j.bbmt.2017.12.660

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：S76 / S77

页数：2

共 50 条

[1] Minimal residual disease negativity and lenalidomide maintenance therapy are associated with superior survival outcomes in multiple myeloma
Patel, Dilan A.
Gopalakrishnan, Ragisha
Engelhardt, Brian G.
McArthur, Evonne
Sengsayadeth, Salyka
Culos, Katie A.
Byrne, Michael
Goodman, Stacey
Savani, Bipin N.
Chinratanalab, Wichai
Jagasia, Madan
Mosse, Claudio A.
Cornell, Robert F.
Kassim, Adetola A.
BONE MARROW TRANSPLANTATION, 2020, 55 (06) : 1137 - 1146
[2] Minimal residual disease negativity and lenalidomide maintenance therapy are associated with superior survival outcomes in multiple myeloma
Dilan A. Patel
Ragisha Gopalakrishnan
Brian G. Engelhardt
Evonne McArthur
Salyka Sengsayadeth
Katie A. Culos
Michael Byrne
Stacey Goodman
Bipin N. Savani
Wichai Chinratanalab
Madan Jagasia
Claudio A. Mosse
Robert F. Cornell
Adetola A. Kassim
Bone Marrow Transplantation, 2020, 55 : 1137 - 1146
[3] In Multiple Myeloma, Minimal Residual Disease (MRD) Is an Early Predictor of Progression and Is Modulated By Maintenance Therapy with Lenalidomide
Gambella, Manuela
Omede, Paola
Oliva, Stefania
Gilestro, Milena
Muccio, Vittorio Emanuele
Drandi, Daniela
Ferrero, Simone
Gay, Francesca
Patriarca, Francesca
Palladino, Carmela
Petrucci, Maria Teresa
Pescosta, Norbert
Liberati, Anna Marina
Caravita, Tommaso
Di Raimondo, Francesco
Rocci, Alberto
Musto, Pellegrino
Boccadoro, Mario
Palumbo, Antonio
BLOOD, 2014, 124 (21)
[4] Clinical implications of loss of minimal residual disease (MRD) negativity in multiple myeloma.
Mohan, Meera
Yarlagadda, Naveen Kumar
Atwal, Dinesh
Pandey, Yadav
Roy, Arya
Parikh, Richa
Lopez, James
Thanendrarajan, Sharmilan
Schinke, Carolina D.
Alapat, Daisy
Van Rhee, Frits
Kendrick, Samantha
Zangari, Maurizio
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[5] Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Multiple Myeloma Patients Treated with Lenalidomide Maintenance Therapy: A Clinical and Correlative Phase 2 Study
Landgren, Ola
Mastey, Donna
Lesokhin, Alexander M.
Smith, Eric L.
Shah, Urvi A.
Mailankody, Sham
Hultcrantz, Malin
Hassoun, Hani
Lu, Sydney X.
Salcedo, Meghan
Diab, Victoria
Werner, Kelly
Rispoli, Jenna
Sams, Allison
Verducci, Dennis
Jones, Katie
Schlossman, Julia
Chansakul, Aisara
Harrison, Angela
Ciardiello, Amanda
Tavitian, Elizabeth
Shekarkhand, Tala
Rustad, Even
Yellapantula, Venkata
Maura, Francesco
Peterson, Tim J.
Devlin, Sean M.
Landau, Heather J.
Scordo, Michael
Chung, David J.
Shah, Gunjan
Lahoud, Oscar B.
Thoren, Katie
Murata, Kazunori
Ramanathan, Lakshmi
Arcila, Maria E.
Ho, Caleb
Roshal, Mikhail
Dogan, Ahmet
Giralt, Sergio
Korde, Neha
BLOOD, 2019, 134
[6] Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition
Pianko, Matthew J.
Devlin, Sean M.
Littmann, Eric R.
Chansakul, Aisara
Mastey, Donna
Salcedo, Meghan
Fontana, Emily
Line, Lilan
Tavitian, Elizabet
Slingerland, John B.
Slingerland, Ann E.
Clurman, Annelie
Gomes, Antonio L. C.
Taur, Ying
Pamer, Eric G.
Peled, Jonathan U.
van den Brink, Marcel R. M.
Landgren, Ola
Lesokhin, Alexander M.
BLOOD ADVANCES, 2019, 3 (13) : 2040 - 2044
[7] Fixed Duration Daratumumab, Ixazomib, Lenalidomide, and Dexamethasone Quadruplet for Newly Diagnosed Multiple Myeloma - MRD Negativity and Survival Outcomes
Kumar, Shaji K.
Laplant, Betsy
Asmus, Erik J.
Buadi, Francis K.
Gonsalves, Wilson, I
Muchtar, Eli
Dingli, David
Thompson, Melanie Ann
Go, Ronald
Warsame, Rahma M.
Kourelis, Taxiarchis
Hwa, Yi L.
Fonder, Amie
Hobbs, Miriam A.
Lacy, Martha Q.
Dispenzieri, Angela
Hayman, Suzanne R.
Leung, Nelson
Binder, Moritz
Rajkumar, S. Vincent
Gertz, Morie A.
Kapoor, Prashant
BLOOD, 2022, 140 : 10142 - 10143
[8] Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Patients with Multiple Myeloma Treated with Continuous Lenalidomide Maintenance Therapy: A Clinical and Correlative Phase 2 Study
Diamond, Benjamin
Korde, Neha
Lesokhin, Alexander M.
Smith, Eric L.
Shah, Urvi A.
Mailankody, Sham
Hultcrantz, Malin
Hassoun, Hani
Lu, Sydney X.
Tan, Carlyn
Massey, Donna
Salcedo, Meghan
Diab, Victoria
Werner, Kelly
Rispoli, Jenna
Sams, Allison
Verducci, Dennis
Jones, Katie
Schlossman, Julia
Chansakul, Aisara
Harrison, Angela
Ciardiello, Amanda Kathryn
Tavitian, Elizabet
Shekarkhand, Tala
Piacentini, Casey
Rustad, Even H.
Yellapantula, Venkata D.
Maura, Francesco
Peterson, Tim J.
Derkach, Andriy
Devlin, Sean
Landau, Heather J.
Scordo, Michael
Chung, David J.
Shah, Gunjan L.
Lahoud, Oscar B.
Thoren, Katie
Murata, Kazunori
Ramanathan, Lakshmi
Arcila, Maria E.
Ho, Caleb
Roshal, Mikhail
Dogan, Ahmet
Giralt, Sergio A.
Landgren, Ola
BLOOD, 2020, 136
[9] Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma A Meta-analysis
Munshi, Nikhil C.
Avet-Loiseau, Herve
Rawstron, Andy C.
Owen, Roger G.
Child, J. Anthony
Thakurta, Anjan
Sherrington, Paul
Samur, Mehmet Kemal
Georgieva, Anna
Anderson, Kenneth C.
Gregory, Walter M.
JAMA ONCOLOGY, 2017, 3 (01) : 28 - 35
[10] Evaluation of Minimal Residual Disease (MRD) Negativity in Patients with Relapsed or Refractory Multiple Myeloma Treated in the Candor Study
Landgren, Ola
Weisel, Katja
Dachs, Laura Rosinol
Moreau, Philippe
Turgut, Mehmet
Hajek, Roman
Mollee, Peter
Kim, Jin Seok
Zhang, Jianqi
Go, Ning
Morris, Christopher L.
Usmani, Saad Z.
BLOOD, 2020, 136

← 1 2 3 4 5 →